Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | PDE8B | O95263 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354644 | 1.00 | ATM (0.51) | ATMPDE8BKDM1AHSD17B10HPGD | |
| SCHEMBL1551631 | 1.00 | ATM (0.51) | ATMPDE8BKDM1AHSD17B10HPGD | |
| SCHEMBL3847564 | 0.98 | ATM (0.50) | ATMPDE8BKDM1AHSD17B10HPGD | |
| SCHEMBL3842356 | 0.98 | ATM (0.50) | ATMPDE8BKDM1AHSD17B10HPGD | |
| SCHEMBL639097 | 0.95 | ATM (0.49) | ATMPDE8BHSD17B10CHEK2SMN1; SMN2 | |
| SCHEMBL115698 | 0.95 | ATM (0.49) | ATMPDE8BHSD17B10CHEK2SMN1; SMN2 | |
| SCHEMBL3420227 | 0.95 | ATM (0.49) | ATMPDE8BHSD17B10CHEK2SMN1; SMN2 | |
| SCHEMBL29551106 | 0.91 | ATM (0.47) | ATMPDE8BKDM1AHSD17B10HPGD | |
| SCHEMBL3422188 | 0.91 | ATM (0.47) | ATMPDE8BKDM1AHSD17B10HPGD | |
| SCHEMBL29550329 | 0.91 | ATM (0.47) | ATMPDE8BKDM1AHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4217361-B1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | GREY WOLF THERAPEUTICS LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| US-20240300976-A1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | Grey Wolf Therapeutics Limited (GB) | 2024-09-12 | — | — | US | disclosed |
| EP-4217361-A1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | Grey Wolf Therapeutics Limited (GB) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022064187-A1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | Grey Wolf Therapeutics Limited (GB) | 2022-03-31 | — | — | WO | disclosed |
| EP-1794129-B1 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-30 | — | — | EP | disclosed |
| EP-1794129-B1 | Synthesis by chiral diamine-mediated asymmetric alkylation | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-30 | — | — | EP | disclosed |
| US-9187435-B2 | Bridged Spiro[2.4]heptane ester derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-11-17 | — | — | US | disclosed |
| EP-2640699-B1 | BRIDGED SPIRO[2,4]HEPTANE ESTER DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-10-07 | — | — | EP | disclosed |
| WO-2006039383-A2 | SYNTHESIS BY CHIRAL DIAMINE-MEDIATED ASYMMETRIC ALKYLATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069250-A1 | Synthesis by chiral diamine-mediated asymmetric alkylation | DENG XIAOHU | 2006-03-30 | — | — | US | disclosed |
| US-6903107-B1 | Serine protease inhibitor | AKZO NOBEL N.V. (NL) | 2005-06-07 | — | — | US | disclosed |
| CN-1146543-C | Serine protease inhibitor | ��˹��ŵ�� | 2004-04-21 | — | — | CN | disclosed |
| CN-1348444-A | Serine protease inhibitor | AKZO NOBEL NV (NL) | 2002-05-08 | — | — | CN | disclosed |
| US-6147088-A | USEFUL FOR THE TREATMENT OF A VARIETY OF SEX-HORMONE RELATED CONDITIONS | MERCK & CO., INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0901471-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5917034-A | Antithrombotic n-amidinopiperidine and benzamidine derivatives | PFIZER INC. (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0901471-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997044321-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069250-A1 | Synthesis by chiral diamine-mediated asymmetric alkylation | SRM, SMOX, DDC | ATM 3394/4885PDE8B 4711/4885KDM1A 2953/4885 |
| US-20240300976-A1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | ERAP1, ERAP2, ERMP1 | ATM 4615/4885PDE8B 4639/4885KDM1A 1138/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | ATM 835/4885PDE8B 3884/4885KDM1A 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.